Denmark leads by a large margin, with 4.60 bio-therapies per million, followed by Switzerland and the United States
Dehydration can be a serious concern
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al
View full details$105.05| /Sold out Vital Pursuit Southwest Style Chicken Fajita Sandwich Melt, 6.7 oz
If you see these patterns in any GLP-1 telehealth platform's marketing, they are the exact claims FDA has called misleading: Calling compounded semaglutide or tirzepatide a "generic" version of Ozempic or Wegovy - compounded drugs are not FDA-approved generics Implying FDA approved or reviewed the compounded product for safety, effectiveness, or quality - the FDA hasn't Claiming the pharmacy is "FDA-approved" or "FDA-licensed" - FDA registers facilities but does not "approve" or "license" compounding pharmacies in the way that phrase implies Branding compounded medication with the telehealth company's name in a way that suggests the telehealth company is the compounder - they're not Any messaging that implies the compounded product is "clinically proven" to perform the same as the FDA-approved branded drug This article avoids all of those patterns
